Refractory anemia with ring sideroblasts and RARS with thrombocytosis

American Journal of Hematology

Volumn 90, Issue 6, 2015, Pages 549-559

  Patnaik, Mrinal M ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTITHROMBOCYTIC AGENT; BUSULFAN; DNA METHYLTRANSFERASE 3A; GRANULOCYTE COLONY STIMULATING FACTOR; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; LENALIDOMIDE; LUSPATERCEPT; SOTATERCEPT; ANGIOGENESIS INHIBITOR; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; THALIDOMIDE; THROMBOPOIETIN RECEPTOR;

ANEMIA; ARTICLE; BONE MARROW BIOPSY; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; ERYTHROID PRECURSOR CELL; GENE; GENE MUTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; IRON OVERLOAD; LOW RISK POPULATION; MEGAKARYOCYTE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS WITH THROMBOCYTOSIS; SF3B1 GENE; SPLICEOSOME; THROMBOCYTE COUNT; THROMBOCYTOSIS; ANALOGS AND DERIVATIVES; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; FEMALE; GENETICS; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; RISK FACTOR;

ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; ANGIOGENESIS INHIBITORS; ASPIRIN; FEMALE; HUMANS; IRON OVERLOAD; JANUS KINASE 2; MALE; MUTATION; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOPOIETIN; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RISK FACTORS; THALIDOMIDE; THROMBOCYTOSIS;

EID: 84929458274     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24038     Document Type: Article

References (80)

1. Swederlow S, Camp E, Harris NL, et al., editor. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
2. Camaschella C. Hereditary sideroblastic anemias: Pathophysiology, diagnosis, and treatment. Semin Hematol 2009;46:371-377.
3. Willekens C, Dumezy F, Boyer T, et al. Linezolid induces ring sideroblasts. Haematologica 2013;98:e138-40. 1.
4. Levi S, Corsi B, Bosisio M, et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001;276:24437-24440.
5. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122:4021-4034.
6. Cazzola M, Invernizzi R, Bergamaschi G, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003;101:1996-2000.
7. Cotter PD, Baumann M, Bishop DF. Enzymatic defect in X-linked sideroblastic anemia: Molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci U S A 1992;89:4028-4032.
8. Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene slc25a38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 2009;41:651-653.
9. Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (abc7) in X-linked sideroblastic anemia and ataxia (XLSA/a). Human Mol Genet 1999;8:743-749.
10. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet TIG 2008;24:398-407.
11. Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in world health organization-defined myelodysplastic syndromes without excess blasts. Blood 2012;119:5674-5677.
12. Swederlow S, Campo E, Harris NL, et al., editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
13. Germing U, Gattermann N, Aivado M, et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): A time-tested distinction. Br J Haematol 2000;108:724-728.
14. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 2000;24:983-992.
15. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-572.
16. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by jak2 V617F mutation. Blood 2006;108:2173-2181.
17. Renneville A, Quesnel B, Charpentier A, et al. High occurrence of jak2 v617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006;20:2067-2070.
18. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009;114:3538-3545.
19. Broseus J, Lippert E, Harutyunyan AS, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014;28:1374-1376.
20. Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis (RARS-T) cases harbor mutations in sf3b1 or other spliceosome genes accompanied by JAK2V617F and asxl1 mutations. Haematologica 2015;100:e125-e127.
21. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
22. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated jak2. N Engl J Med 2013;369:2391-2405.
23. Patnaik MM, Belachew A, Finke C, et al. CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia 2014;28:1370-1371.
24. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
25. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic sf3b1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384-1395.
26. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012;26:542-545.
27. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 2014;124:1513-1521.
28. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of sf3b1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118:6239-6246.
29. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012;120:3173-3186.
30. Nikpour M, Scharenberg C, Liu A, et al. The transporter abcb7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2013;27:889-896.
31. Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012;97:1036-1041.
32. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012;26:1135-1137.
33. Patnaik MM, Lasho TL, Finke CM, et al. Spliceosome mutations involving srsf2, sf3b1, and u2af35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88:201-206.
34. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:2497-2506.
35. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376-3382.
36. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119:3211-3218.
37. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
38. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
39. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 2008;113:1351-1361.
40. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
41. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
42. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013;122:2943-2964.
43. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:97-108.
44. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
45. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527-536.
46. Jadersten M, Montgomery SM, Dybedal I, et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005;106:803-811.
47. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011;16(Suppl3):35-42.
48. Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-393.
49. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 2008;111:574-582.
50. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-557.
51. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93.
52. Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010;12:586-597.
53. Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012;120:386-394.
54. Valent P, Krieger O, Stauder R, et al. Iron overload in myelodysplastic syndromes (MDS)-Diagnosis, management, and response criteria: a proposal of the austrian MDS platform. Eur J Clin Invest 2008;38:143-149.
55. Greenberg PL, Rigsby CK, Stone RM, et al. NCCN task force: transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw 2009;7(Suppl9):S1-S16.
56. Chee CE, Steensma DP, Wu W, et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008;83:611-613.
57. Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009;84:265-267.
58. Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndrome-cui bono? Leukemia 2009;23:1373.
59. Patnaik M, Lasho T, Finke C, et al. WHO-defined 'myelodysplastic syndrome with isolated del (5q)'in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of jak2, MPL and IDH mutations. Leukemia 2010;24:1283-1289.
60. Trottier BJ, Burns LJ, DeFor TE, et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: A prospective cohort study using R2-MRI-measured liver iron content. Blood 2013;122:1678-1684.
61. Durairaj S, Chew S, Hyslop A, et al. Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates. Am J Hematol 2011;86:406-410.
62. Cermak J, Jonasova A, Vondrakova J, et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011;35:217-227.
63. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008;83:398-402.
64. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
65. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol 2006;24:3895-3903.
66. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31:2428-2436.
67. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-585.
68. Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis. J Clin Oncol 2013;31:2662-2670.
69. Jeromin S, Haferlach T, Grossmann V, et al. High frequencies of sf3b1 and jak2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 2013;98:e15-e17.
70. Huls G, Mulder AB, Rosati S, et al. Efficacy of single-agent lenalidomide in patients with jak2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood 2010;116:180-182.
71. Michiels JJ, Berneman Z, Schroyens W, et al. The paradox of platelet activation and impaired function: Platelet-von willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32:589-604.
72. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood 2011;117:5857-5859.
73. Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014;124:2611-2612.
74. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:162-173.
75. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-1210. quiz 1387.
76. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.
77. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
78. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-3072.
79. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-5424.
80. Shvidel L, Sigler E, Haran M, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia 2007;21:2071-2072.